ArticleAntimicrobial agents and chemotherapy2003
Gastric transitional zones, areas where Helicobacter treatment fails: results of a treatment trial using the Sydney strain mouse model.
Article in Antimicrobial agents and chemotherapy, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 31 citations in OpenAlex.
- Research progress of potassium-competitive acid blockers in the treatment ofAnnals of medicine · 2025Review
- Article
- Article
- Article
- VacA generates a protective intracellular reservoir for Helicobacter pylori that is eliminated by activation of the lysosomal calcium channel TRPML1.Nature microbiology · 2019Article
- Helicobacter pylori infection progresses proximally associated with pyloric metaplasia in age-dependent tendency: a cross-sectional study.BMC gastroenterology · 2018Article
- Coating nanoparticles with gastric epithelial cell membrane for targeted antibiotic delivery againstAdvanced therapeutics · 2018Article
- Helicobacter pylori Biofilm Formation and Its Potential Role in Pathogenesis.Microbiology and molecular biology reviews : MMBR · 2018Review
- Pyridodiazepine amines are selective therapeutic agents for helicobacter pylori by suppressing growth through inhibition of glutamate racemase but are predicted to require continuous elevated levels in plasma to achieve clinical efficacy.Antimicrobial agents and chemotherapy · 2015Article
- Early or late antibiotic intervention prevents Helicobacter pylori-induced gastric cancer in a mouse model.Cancer letters · 2014Article
- Preclinical studies of amixicile, a systemic therapeutic developed for treatment of Clostridium difficile infections that also shows efficacy against Helicobacter pylori.Antimicrobial agents and chemotherapy · 2014Article
- Anti-Helicobacter pylori potential of artemisinin and its derivatives.Antimicrobial agents and chemotherapy · 2012Article
- Docosahexaenoic acid inhibits Helicobacter pylori growth in vitro and mice gastric mucosa colonization.PloS one · 2012Article
- Gastric infection by Helicobacter pylori.Current gastroenterology reports · 2011Review
- Transfer and distribution of amoxicillin in the rat gastric mucosa and gastric juice and the effects of rabeprazole.Acta pharmacologica Sinica · 2010Article
- Combination of sulindac and antimicrobial eradication of Helicobacter pylori prevents progression of gastric cancer in hypergastrinemic INS-GAS mice.Cancer research · 2009Article
- Helicobacter pylori eradication prevents progression of gastric cancer in hypergastrinemic INS-GAS mice.Cancer research · 2008Article
- The Helicobacter pylori chemotaxis receptor TlpB (HP0103) is required for pH taxis and for colonization of the gastric mucosa.Journal of bacteriology · 2006Article
- Role of rapid urease test and histopathology in the diagnosis of Helicobacter pylori infection in a developing country.BMC gastroenterology · 2005Article
- Evaluation of antibiotic treatment against "Candidatus Helicobacter suis" in a mouse model.Antimicrobial agents and chemotherapy · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current combination therapies cure Helicobacter pylori infection in 75 to 85% of cases. However, many treatment failures are not explained by antibiotic resistance. Our goal was to explore treatment failures under in vivo conditions by using the H. pylori Sydney strain (SS1) mouse model. Mice infected with H. pylori (SS1) were treated with monotherapies or combination therapies used in human trials. Bacterial levels and distribution of organisms within the stomach were assessed 24 h after treatment to determine clearance and location of treatment failures and 29 days after treatment to determine cure rates. Except for treatment with metronidazole, mono- and dual therapies did not cure infection but resulted in decreases in bacterial levels and differences in distribution within the stomach. In cases of treatment failure when clarithromycin was used, omeprazole and dual therapy with omeprazole and amoxicillin resulted in organisms being cleared from the antrum, but organisms remained in the antrum-body transitional zone. The triple therapies of OMC and bismuth subcitrate, metronidazole, and tetracycline were successful in eradicating infection. Except for metronidazole monotherapy and triple therapy with OAC, there was good correlation between the Sydney strain mouse model and humans with respect to the success of antimicrobial therapy. The antrum-body transitional zone was identified as a sanctuary site in treatment failure. This could result from antimicrobial agents not functioning effectively at this site or bacteria in this location expressing products that protect them against antimicrobial agents. This is the first demonstration of a possible sanctuary site as a reason for failure of therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.